Nature (journal)

COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology

Retrieved on: 
Monday, July 17, 2023
Psilocybin, The New England Journal of Medicine, COMPASS, Nature (journal), Selective serotonin reuptake inhibitor, Patient, CMPS, Headache, SSRI, Mental health, Safety, Dietary supplement, Pharmaceutical industry, MADRS

The exploratory phase 2 clinical trial used an open-label, fixed-dose design to investigate the safety and efficacy of a single dose of 25mg of COMP360 psilocybin with psychological support, in addition to an SSRI, in 19 participants experiencing treatment-resistant depression.

Key Points: 
  • The exploratory phase 2 clinical trial used an open-label, fixed-dose design to investigate the safety and efficacy of a single dose of 25mg of COMP360 psilocybin with psychological support, in addition to an SSRI, in 19 participants experiencing treatment-resistant depression.
  • Guy Goodwin, Chief Medical Officer at COMPASS Pathways, said, “It has long been thought that SSRIs could interfere with the potential therapeutic effect of psilocybin.
  • COMPASS is currently conducting a phase 3 clinical program of COMP360 psilocybin treatment in treatment-resistant depression, the largest of its kind ever conducted.
  • This program follows positive results from COMPASS’s phase 2b trial published in the New England Journal of Medicine .

Head of Insilico Medicine’s Hong Kong R&D Center to Give Keynote on AI Drug Discovery at HKUST Big Data Institute

Retrieved on: 
Thursday, May 4, 2023
Learning, In silico, Pharma, DNA, University, Nature, Therapy, Hepatocellular carcinoma, Acceleration, COVID-19, HKT, Ageing, Cancer, ALS, Intelligence, Chemistry, Research, Gene expression, Fosun International, Doctor of Philosophy, Glioblastoma, Fibrosis, Publication, Biomedicine, Patient, Amyotrophy, Insilico Medicine, Drug discovery, Sanofi, Frontiers Media, Nature (journal), IPF, AlphaFold, Idiopathic pulmonary fibrosis, Medical device, Oncotarget, AI

Hong Kong, May 04, 2023 (GLOBE NEWSWIRE) -- Frank Pun, PhD, Head of the Hong Kong R&D Center of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will give a keynote presentation titled “How AI is Transforming Drug Discoveries” at the Hong Kong University of Science and Technology Big Data Institute Workshop on Big Data and Biomedical & Chemistry Science on May 8, 10am, HKT.

Key Points: 
  • Hong Kong, May 04, 2023 (GLOBE NEWSWIRE) -- Frank Pun, PhD, Head of the Hong Kong R&D Center of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will give a keynote presentation titled “How AI is Transforming Drug Discoveries” at the Hong Kong University of Science and Technology Big Data Institute Workshop on Big Data and Biomedical & Chemistry Science on May 8, 10am, HKT.
  • The Company’s software is trained on aging and focused on diseases with high unmet need, and two of its AI-designed drugs have reached clinical trials.
  • Insilico first proved the concept of an AI drug discovery engine in 2016 – screening 72 million compounds and identifying candidate molecules with anti-cancer properties in a paper published in Oncotarget .
  • Dr. Pun leads a team of application scientists in Hong Kong who are further developing PandaOmics , the AI-enabled biological target discovery engine of Insilico’s end-to-end platform and has published widely in top peer-reviewed journals related to his research in AI drug discovery.

BIAL Award in Biomedicine worth 300,000 Euros

Retrieved on: 
Wednesday, April 26, 2023
BioNTech, The New England Journal of Medicine, European Medical Association, The BMJ, European Research Council, Medical journal, COVID-19 vaccine, Perelman School of Medicine at the University of Pennsylvania, Medicina, Jury, University, Nature (journal), Medical Faculty Associates, Messenger, Bangladesh Technical Education Board, Harvard Medical School, Panel, Biology, COVID-19, Council, Saint Andrew's Society, Bial, Medical device, Nursing, Pharmaceutical industry, California Institute of Technology, Biomedicine, Psychology, Neuroscience

TROFA, Portugal, April 26, 2023 /PRNewswire/ -- The third edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is now underway, with nominations open until 30 June. With the amount of 300 thousand Euros, this award aims to recognise a work of a broad biomedical nature with exceptional quality and scientific relevance results published within the last ten years.

Key Points: 
  • TROFA, Portugal, April 26, 2023 /PRNewswire/ -- The third edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is now underway, with nominations open until 30 June.
  • With the amount of 300 thousand Euros, this award aims to recognise a work of a broad biomedical nature with exceptional quality and scientific relevance results published within the last ten years.
  • Candidates for this international award may be nominated by members of the Jury, members of the Scientific Board of the BIAL Foundation, previous BIAL Award winners, Scientific Societies, Boards or Deans of Medical Faculties, Heads of leading research institutes, and Boards or Heads of prestigious Academies.
  • The BIAL Award in Biomedicine takes place biannually, in odd-numbered years, alternating with the Prémio BIAL de Medicina Clínica.

Lam Research AI Study Identifies Game-Changing Development Approach for Speeding Up, Slashing Cost of Chip Innovation

Retrieved on: 
Monday, April 10, 2023
Nature (journal), Human, Lam Research, Media Resource Control Protocol, Intuition, Media, Research, LRCX, Plasma, System, Engineering, Physics, Artificial intelligence, Knowledge, Ecosystem, AI, Silicon, Medical device, Management, Nature, Lam

The study found that a "human first, computer last" approach can reach process engineering targets dramatically faster and at half the cost compared to today's approach.

Key Points: 
  • The study found that a "human first, computer last" approach can reach process engineering targets dramatically faster and at half the cost compared to today's approach.
  • Lam Research study in Nature points to new AI-human approach for the hardest part of chip development; costs cut by 50%.
  • Seeking a more efficient approach, researchers at Lam put talented process engineers head-to-head against AI-enabled computer algorithms in the study.
  • Media Resources: Visit the Lam Newsroom to download the full study, "Human-machine collaboration for improving semiconductor process development," an infographic and additional media resources.

Fluent BioSciences announces Nature Biotechnology journal publication, "Microfluidics-free single-cell genomics with templated emulsification", showcasing the foundational technology underlying PIPseq™

Retrieved on: 
Tuesday, March 7, 2023
Assistant, Biological engineering, Nature, Cell, T100, DOI, T20, Nature (journal), SVP, Disease, University of California, Berkeley, University, Fine chemical, Fluency

WATERTOWN, Mass., March 7, 2023 /PRNewswire/ -- Fluent BioSciences, a leading life sciences company focused on revolutionizing single cell analysis through simple, cost-effective and scalable solutions, announces the Nature Biotechnology Journal publication (DOI: 10.1038/s41587-023-01685-z) describing the foundational technology underlying PIPseq and demonstrating its flexibility across emulsification formats, scalability in cell capture and compatibility with multi-omic measurements in clinical samples.

Key Points: 
  • The Nature Journal publication follows the recent release of Fluent's v4.0 chemistry with significant performance enhancements and the highest cell capture rate in the market.
  • WATERTOWN, Mass., March 7, 2023 /PRNewswire/ -- Fluent BioSciences, a leading life sciences company focused on revolutionizing single cell analysis through simple, cost-effective and scalable solutions, announces the Nature Biotechnology Journal publication (DOI: 10.1038/s41587-023-01685-z) describing the foundational technology underlying PIPseq and demonstrating its flexibility across emulsification formats, scalability in cell capture and compatibility with multi-omic measurements in clinical samples.
  • "Fluent has commercialized this technology and recently released our PIPseq v4.0 3' Single Cell RNA series of reagent kits which bring significant enhancements in performance, capture rate, and scale", states author Kristina Fontanez, SVP of Product Development at Fluent BioSciences.
  • To learn more about PIPseq and the v4.0 product offerings, please contact [email protected] .

Breakthrough CRISPR Technology Study Published in Nature

Retrieved on: 
Friday, January 13, 2023
Food, Beverage, Retail, Other Professional Services, Food Tech, Research, Other Policy Issues, Finance, Supply Chain Management, Professional Services, Genetics, Science, Technology, Public Policy, Government, Biotechnology, Agriculture, Alternative Energy, Natural Resources, Health, Energy, CRISPR, Gene, Nature (journal), Learning, DNA, NYSE, Abortive, Gene editing, Biology, Research and development, Protein, RNA, Framework, Enzyme, Taste, Multimedia, Plant, United States Air Force Scientific Advisory Board, Vaccine, Nature, Benson E. Hill

A groundbreaking research study by a team that included scientists from Benson Hill , Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), has been published this month in Nature, the world’s leading multidisciplinary journal, highlighting a new mechanism for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology.

Key Points: 
  • A groundbreaking research study by a team that included scientists from Benson Hill , Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), has been published this month in Nature, the world’s leading multidisciplinary journal, highlighting a new mechanism for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology.
  • View the full release here: https://www.businesswire.com/news/home/20230113005450/en/
    A groundbreaking research study by a team that included scientists from Benson Hill, Inc., has been published this month in Nature, the world’s leading multidisciplinary journal, highlighting a new mechanism for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology.
  • The study concludes that Cas12a2 holds substantial potential for CRISPR technologies as a biotechnological tool.
  • More specifically, the study notes that RNA targeted CRISPR activity could enable programmable killing of multiple cell types.

SimBioSys Welcomes Dr. Anant Madabhushi and Dr. Donald Berry to its Scientific Advisory Board

Retrieved on: 
Wednesday, September 7, 2022
Technology, Research, Biotechnology, Health, General Health, Data Management, Science, Artificial Intelligence, Oncology, Thomson Reuters, Lung cancer, University, Breast cancer, Engineering, Case Western Reserve University, Technology, Cancer, Georgia Institute of Technology College of Computing, Biomedicine, Research, Nature (journal), Artificial intelligence, Emory University, Doctor of Philosophy, Monroe Dunaway Anderson, SAB, Disease, Precision medicine, Department, Computational imaging, Intelligence, Computer, Particle-size distribution, Duke University, Georgia Tech, Deep learning, Wallace H. Coulter Department of Biomedical Engineering, Case School of Engineering, Center, Medicine, History, Anant Madabhushi, Case School of Dental Medicine, Biomedical engineering, LLC, 2021 Essex County Council election, Clinical trial, Patient, Medical device, Pharmaceutical industry, Biostatistics, Simbiosys

SimBioSys, a technology company developing a first of its kind precision medicine platform, combining biophysical modeling and artificial intelligence, today announced the appointment of Anant Madabhushi, PhD and Donald Berry, PhD to its scientific advisory board (SAB).

Key Points: 
  • SimBioSys, a technology company developing a first of its kind precision medicine platform, combining biophysical modeling and artificial intelligence, today announced the appointment of Anant Madabhushi, PhD and Donald Berry, PhD to its scientific advisory board (SAB).
  • With an impressive history, authoring over 400 peer-reviewed papers, and more than 100 patents, the expertise offered by Dr. Madabhushi is invaluable.
  • On joining SimBioSys Advisory Board, Dr. Madabushi shares, "I have devoted my career to developing technologies in cancer research towards making an impact in patients' lives.
  • Both Dr. Madabhushi and Dr. Berry will help SimBioSys continue to expand its already vibrant communication channels among research communities.

DGAP-News: Is Nocera Providing Local Solutions For A Global Food Crisis?

Retrieved on: 
Monday, August 22, 2022
Nature (journal), LSG, Food, CEO, Recycling, Advertising, EPC, NASDAQ, Engineering, OTCQX, Solution, Recirculating aquaculture system, Research report, Farmer, Water, Revolution, Aquaculture, Interview, RAS, Farm, Efficiency, Food chain, Industry, Environment, Offshore aquaculture, Nocera

Is Nocera Providing Local Solutions For A Global Food Crisis?

Key Points: 
  • Is Nocera Providing Local Solutions For A Global Food Crisis?
  • Learn more about Nocera Inc. by gaining access to the latest research report
    The world is no stranger to food crises.
  • One company that seems to be taking the food problem seriously is Nocera Inc. (NASDAQ: NCRA).
  • Nocera describes itself as an innovative recirculating aquaculture system (RAS) production and consulting company, providing solutions to the land-based fish farm industry.

Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade

Retrieved on: 
Thursday, July 28, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Metastasis, Brain, University, Phenotype, Chymotrypsinogen, PRP, EMT, Tissue, U.S. Securities and Exchange Commission, Enzyme, Research, Pancreas, Trypsinogen, CSC, Tumor microenvironment, Multimedia, Cancer, Lung, PPCB, MB, Recurrence, Liver, Immunotherapy, FDA, Company, MD, Science, Security (finance), Patient, Differentiable function, OTCQB, Malignancy, Prostate, Bachelor of Medicine, Bachelor of Surgery, Survival, Expert Opinion on Biological Therapy, Accounting, Entrepreneurship, Kidney, CSCS, Breast, Growth, Scientific Reports, Budget, B cell, Wound healing, Nature (journal), Pharmaceutical industry, Medical imaging

PRP is a proenzyme therapy for the treatment and prevention of metastatic cancer from solid tumors.

Key Points: 
  • PRP is a proenzyme therapy for the treatment and prevention of metastatic cancer from solid tumors.
  • This unique approach could become an effective tool in the fight against metastatic cancer, which is the main cause of patient death for sufferers.
  • When CSCs undergo the EMT process, they become motile and invasive, with an ability to spread into surrounding tissues.
  • Further research is in progress with the Companys joint research partners focusing on the effects of PRP on the tumor microenvironment.

First Blood Test to Diagnose Bipolar Disorder

Retrieved on: 
Thursday, June 9, 2022
Biomarker, Outpatient clinic (hospital department), Translational Psychiatry, Research, Mental health, Cyclothymia, Bipolar disorder, RNA editing, Artificial intelligence, Depression, Depressive, University, RNA, Professor, Partnership, Psychiatry, Innovation, Blood, Gene, IVDR, Conditional sentence, European Institute, Patient, Lists of diseases, Gene expression, Nature (journal), Wilfrid Sellars, UD, Diagnosis, Center, Department, BD, Technology, Medical device, Pharmaceutical industry, Synlab Group, Nature

MONTPELLIER, France and PARIS, June 9, 2022 /PRNewswire/ -- Alcediag, a French company specializing in precision psychiatry and a pioneer in biological diagnosis in mental health, announces the publication, in Nature: Translational Psychiatry, of a study that identified a panel of six blood biomarkers, major hallmarks of bipolar disorder.

Key Points: 
  • These results, recently published in the leading scientific journal Nature, have led to the development of the first diagnostic blood test for this disorder that affects more than 60 million people worldwide.
  • While the number of people suffering from depression is estimated at 300 million worldwide, up to 40% of them could actually be affected by bipolar disorder.
  • Yet, the management and treatments for bipolar disorder and depression differ significantly, making timely and reliable diagnosis paramount.
  • For the first time, the study led by Alcediag, including a cohort of 410 subjects, provides such a reliable, accurate test capable of differentiating the depressive phases of bipolar disorder from unipolar depression.